Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative

Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative

Sickle cell disease (SCD) is an inherited blood disorder that affects about 100,000 people in the U.S., primarily Blacks/African-Americans. A multitude of complications negatively impacts quality of life. Hydroxyurea has been FDA approved since 1998 as a disease-modifying therapy for SCD, but is und...

Full description

Bibliographic Details
Main Authors: Marsha J. Treadwell, Lisa Du, Neha Bhasin, Anne M. Marsh, Theodore Wun, M. A. Bender, Trisha E. Wong, Nicole Crook, Jong H. Chung, Shannon Norman, Nicolas Camilo, Judith Cavazos, Diane Nugent
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Genetics
Subjects:
sickle cell disease
barriers to adherence
disease modifying therapies
models -adherence
hydroxyurea
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.921432/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2022.921432/full

Similar Items